Recently, Snibe has passed the IFCC External Quality Assessment Scheme for Reference Laboratories in Laboratory Medicine (IFCC-RELA), and 9 assays from Snibe reference laboratory achieved excellent results during the assessment, including 25-OH-Vitamin D3, 17-OH Progesterone, AP, ALT, Amylase, AST, CK, GGT and LDH.

Hepatocellular carcinoma (HCC) is one of the common malignant tumors. Due to the insidious onset, most patients with HCC have lost the opportunity for effective treatment when diagnosed, resulting in a low survival rate. It is urged to develop more effective diagnostic strategies to improve the early detection rate. Aiming to further explore the clinical application of serological indicators in early screening and diagnosis of HCC, the School of Basic Medical Sciences Peking University (SBMS, PKU) held an online meeting on June 25, 2022, to officially announce the launch of the project: Multicenter Study in Evaluating the Combination of Multiple Indicators in HCC Screening. Snibe is the exclusive industry supporter.

Recently, Snibe receives the CE mark for its RapisafeTM SARS-CoV-2 Ag test (Colloidal Gold), which further confirmed that the quality of our Self-Testing kits is in line with international standards.

On May 26,2022, Snibe has received the CE List A Certificate for 5 MAGLUMI® CLIA immunoassays of Hepatitis B virus (HBV) detection, covering Anti-HBc IgM, Anti-HBs, HBeAg, Anti-HBe, and anti-HBC. Up to now, 6 CLIA immunoassays for HBV detection have all obtained CE List A Certificate, besides the MAGLUMI® HBsAg (CLIA) Assay.

Snibe received the CE certificate (List A) for MAGLUMI® HBsAg (CLIA) assay On March 11, 2022. It further proves the high reliability of the quality and performance of Snibe products, as well as a verification of Snibe’s leading position in the field of chemiluminescence.